Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Flerie is a life science investment firm founded in 2011, with offices in Stockholm and London. The firm manages a $250 million fund and has over SEK 2,500 million in assets under management, supporting a portfolio of 25 companies across Europe, Israel, and the United States.
Flerie primarily invests in the drug development sector, including cell and gene therapy, vaccines, biologics, and small molecules. They engage with companies from pre-clinical to clinical phases and support their commercial growth towards profitability, investing in both private and selective public companies.
Notable companies in Flerie's portfolio include Alder Therapeutics, developing therapies from pluripotent stem cells; Amarna Therapeutics, focused on gene therapies for rare diseases; AnaCardio, developing novel inotropic agents; Atrogi, working on an oral treatment for type 2 diabetes; Bonsai Biotherapeutics, developing drug candidates for immune tolerance; and Buzzard Pharmaceuticals, working on an interleukin-1 inhibitor for solid tumors.
Submit through their form at https://flerie.com/en/contact/.
Flerie often leads investment rounds, particularly in the drug development sector, where they can provide significant resources and expertise.
Flerie is open to follow-on investments, especially for companies demonstrating progress through clinical phases and moving towards profitability.
Flerie's current fund size is $250 million, which they allocate across various stages of investment from pre-seed to Series C.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.